Background International guidelines have endorsed the use of edoxaban or rivaroxaban as
an alternative to low-molecular-weight heparin (LMWH) for the treatment of acute venous …

Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early
reports describe high venous thromboembolism (VTE) and disseminated intravascular …

Critically ill patients with COVID-19 are at increased risk for thrombotic complications which
has led to an intense debate surrounding their anticoagulation management. In the absence …

The coexistence of coronavirus disease 2019 (COVID-19) and pulmonary embolism (PE),
two life-threatening illnesses, in the same patient presents a unique challenge. Guidelines …

Importance COVID-19 is a life-threatening illness for many patients. Prior studies have
established hematologic cancers as a risk factor associated with particularly poor outcomes …

Background: Hypercoagulability may be a key mechanism of death in patients with
coronavirus disease 2019 (COVID-19). Objective: To evaluate the incidence of venous …

Importance Non-Hispanic Black individuals experience a higher burden of COVID-19 than
the general population; hence, there is an urgent need to characterize the unique clinical …

Abstract Background/Objective Before approval of andexanet alfa, off‐label treatment with 4‐
factor prothrombin complex concentrate (4F‐PCC) was often utilized for the management of …

Platelet autoantibody (PA) testing has previously shown poor sensitivity for immune
thrombocytopenia (ITP) diagnosis, but no previous study used both 2011 American Society …

Bleeding is the most common complication of anticoagulant use. The evaluation and
management of the bleeding patient is a core competency of emergency medicine. As the …